BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
Condition(s):NSCLCLast Updated:September 13, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):NSCLCLast Updated:September 13, 2023Recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:August 1, 2018Terminated
Condition(s):ALK-positive Non-small-cell Lung CancerLast Updated:February 2, 2022Completed
Condition(s):NSCLCLast Updated:August 29, 2023Active, not recruiting
Condition(s):Non Small Cell Lung CancerLast Updated:March 15, 2024Not yet recruiting
Condition(s):Unresectable Locally Advanced NSCLCLast Updated:October 30, 2012Completed
Condition(s):Lung CancerLast Updated:December 8, 2021Unknown status
Condition(s):Non-small Cell Lung CancerLast Updated:December 6, 2017Withdrawn
Condition(s):Metastatic Non Small Cell Lung Cancer; Recurrent Non Small Cell Lung CancerLast Updated:April 3, 2020Completed
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:April 28, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.